About Enveda
Enveda is a Healthcare company based in Boulder (United States) founded in 2019 by Viswa Colluru. Provider of AI-based platform to decipher the chemistry of nature and develop new medicines. Enveda has raised $845 million across 12 funding rounds from investors including Microsoft, SVB and Lightspeed Venture Partners. The company has 153 employees. Enveda was last valued at $1.2 billion in December 2025. Its chief executive, as recorded, is Viswa Colluru. Its website enveda.com draws about 12 thousand monthly visits. Its Indian entity Enveda Therapeutics India Private Limited reported revenue of ₹32.77 Cr. Enveda offers products and services including Enveda Platform. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its competitors include NTxBio, Nimble Therapeutics and Applied BioMath; 3 of its 3 listed competitors have raised funding.
Company details
Enveda was founded in 2019 in Boulder, United States, as a biotechnology company focused on drug discovery. Advanced computational methods and metabolomics are employed by the platform to analyze natural chemical compounds and identify potential treatments for diseases. Drug development processes are accelerated through the integration of nature-derived chemical insights, supporting research in the pharmaceutical sector.
- Headquarters Boulder, United States
- Employees 153
- Founders Viswa Colluru
- Stage Unicorn
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website enveda.com
- Social LinkedIn X Facebook
- Legal Name Enveda Therapeutics India Private Limited
- Date of Incorporation 08 Aug, 2019
- Jurisdiction Visakhapatnam, Andhra Pradesh, India
- Indian entity revenue₹32.77 Cr
FY 2023 · +117% YoY
- Indian entity net profit₹5.69 Cr
FY 2023 · 17% margin
- Indian entity EBITDA₹10.91 Cr
FY 2023 · 33% margin
- Total Equity Funding$845M (USD)
in 12 rounds
- Latest Funding Round$311M (USD), Series E
Sep 2026
- InvestorsMicrosoft
& 37 more
- Employee Count153
Associated legal entities of Enveda
Enveda operates through Enveda Therapeutics India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2023) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Enveda Therapeutics India Private Limited CIN U73100AP2019FTC112638 | Active | 08 Aug 2019 | Visakhapatnam, Andhra Pradesh | ₹32.8 Cr | 103 | 2 | View details |
Products & Services of Enveda
Enveda offers a comprehensive portfolio of products and services, including Enveda Platform.
Platform analyzes natural molecules for faster medicine development
Funding Insights of Enveda
Enveda has successfully raised a total of $845M across 12 strategic funding rounds. The most recent funding activity was a Series E round of $311 million completed in September 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $845M
- Total Rounds 12
- Last Round Series E — $311M
- First Round $150,000
(Jan 2019)
- Investors Count 38
Latest 10 of 12 funding rounds of Enveda with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2026 | $311M | Series E | – | Catalio Capital Management | |
| Sep 2025 | $150M | Series D | – | Premji Invest | |
| Feb 2025 | Series C | – | – | ||
| Nov 2024 | $130M | Series C | – | Kinnevik, FPV Ventures | |
| Jun 2024 | $55M | Series B | – | – | |
| Apr 2023 | $51M | Series B | – | – | |
| Dec 2022 | Debt – Venture | – | – | ||
| Dec 2022 | $62.46M | Series B | – | Dimension | |
| Jun 2021 | $51M | Series A | – | Lux Capital | |
| Aug 2020 | $5M | Seed | – | True Ventures |
| Date | Valuation | Stage |
|---|
Full valuation and stage history of Enveda
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $1.2B (Dec 2025). 38 investors in total: 34 institutional and 4 angel.
Investors in Enveda
Enveda has secured backing from 38 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Microsoft, SVB and Lightspeed Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments are directed toward multiple sectors by Kinnevik. | 1936 | kinnevik.com | Stockholm, Sweden | |
Provides venture capital for technology startups and enterprise innovations worldwide. | premjiinvest.com | Bengaluru, India | ||
Seed and early-stage technology companies are funded by Lux Capital. | luxcapital.com | Menlo Park, United States | ||
Dimension is focused on investments at the intersection of technology and life sciences. | dimensioncap.com | |||
Venture capital firm supporting AI founders through investments and community. | trueventures.com | |||
Investments are provided to mission-driven founders by FPV Ventures. | fpvventures.com | San Francisco, United States | ||
Level Ventures is engaged in investing in venture firms globally. | levelvc.com | New York, United States | ||
Tech & Life Science focused VC firm investing in the US | jazzvp.com | San Francisco, United States | ||
Early-stage impact-driven fintech and healthcare startups are accelerated. | wireframevc.com | San Francisco, United States | ||
Amino Collective is engaged in backing innovative startup founders. | aminocollective.com |
Investor details for Enveda
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Enveda Therapeutics India Private Limited (Enveda)
Enveda Therapeutics India Private Limited is the primary company behind Enveda. The board of Enveda Therapeutics India Private Limited currently have 2 directors; the longest-serving is Viswa Teja Saraschandra Srinivasa Colluru, appointed in 2019.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Viswa Teja Saraschandra Srinivasa Colluru DIN 08533250 | Director | 08 Aug 2019 | 7 yrs 2 mo | Enveda Therapeutics India Private Limited |
| Nookayyasatya Prakasa Krishna Rao Colluru DIN 08533251 | Director | 08 Aug 2019 | 7 yrs 2 mo | Enveda Therapeutics India Private Limited |
People of Enveda
1 people are tracked at Enveda (1 in leadership); the tracked headcount is 153.
| Name | Role | Group |
|---|---|---|
| Founder & CEO | Leadership |
Complete people profiles for Enveda
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Enveda
Figures of Enveda Therapeutics India Private Limited, the primary company behind Enveda, for FY 2023. Revenue was ₹32.77 Cr (+117% year on year). Net profit was ₹5.69 Cr (17% margin). EBITDA was ₹10.91 Cr (33% margin). Revenue has grown at a compounded annual rate of +222% over three years.
- ₹32.77 CrRevenue · FY 2023 · +117% YoY
- ₹5.69 CrNet profit · 17% margin
- ₹10.91 CrEBITDA · 33% margin
- ₹49.6 LakhPaid-up capital
- 103Employees (provident fund records)
- +222%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Enveda Therapeutics India Private Limited are on its company page.
Detailed financial statements for Enveda
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Enveda
4 dated milestones of Enveda across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Enveda is founded.
- Funding First funding round of $150K.
- Milestone Reaches Unicorn status.
- Funding Latest funding round, Series E, of $311.0M.
Competitors of Enveda
Enveda has 3 listed competitors in our database, 3 of them funded. They include NTxBio, Nimble Therapeutics and Applied BioMath.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ntxbio.com | 2016 | Santa Fe, United States | $74.76M | Provider of bio informatics platform to develops biologics and therapeutics | ||
| nimbletherapeutics.com | 2019 | Madison, United States | $10M | 24 | Combinatorial chemistry services for peptide-based drug discovery are provided. | |
| appliedbiomath.com | 2013 | Cambridge, United States | $2.32M | 61 | Systems biology and pharmacology modeling services to aid drug discovery and development |
Detailed competitors of Enveda
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Enveda
The website of Enveda (enveda.com) receives about 12.2K visits a month and ranks #2,110,963 among all websites worldwide, #2,875 in Biotechnology and Pharmaceuticals.
- Monthly visits12.2K
▲ 13.3% vs previous month
- Unique visitors5.6K
per month
- Global rank#2,110,963
among all websites
- Category rank#2,875
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.9
- Average visit47 sec
- DevicesDesktop 62% · Mobile 38%
Websites whose visitors overlap most with Enveda. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
thepharmaletter.com | thepharmaletter.com | 100% | #486,864 | – | |
| pharmaceutical-technology.com | 100% | #316,052 | View details | ||
firstwordpharma.com | firstwordpharma.com | 100% | #237,108 | – |
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Enveda (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Enveda
Complete news archive for Enveda
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enveda
Enveda was founded in 2019.
Enveda is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
Viswa Colluru is the CEO of Enveda, as recorded in our data. They have also founded this company.
Enveda is a funded company, having raised a total of $845M across 12 funding rounds to date. The company's 1st funding round was a Seed of $5M, raised on Jan 2019.
Enveda has 153 employees.
The primary company behind Enveda, Enveda Therapeutics India Private Limited, reported revenue of ₹32.77 Cr for FY 2023, up 117% year on year.
Enveda was founded in 2019 in Boulder, United States, as a biotechnology company focused on drug discovery. Advanced computational methods and metabolomics are employed by the platform to analyze natural chemical compounds and identify potential treatments for diseases. Drug development processes are accelerated through the integration of nature-derived chemical insights, supporting research in the pharmaceutical sector.
Enveda's top competitors include NTxBio, Nimble Therapeutics and Applied BioMath.
Enveda offers Enveda Platform.
Enveda has 38 investors. Key investors include Microsoft, SVB, Lightspeed Venture Partners, Sanofi, and Baillie Gifford.
The valuation of Enveda is $1.2B as of Dec 2025.
Enveda operates through Enveda Therapeutics India Private Limited.